Other
Dec 2024BioAge discontinued the STRIDES Phase 2 obesity trial of azelaprag after transaminitis/liver-enzyme elevations were observed in some participants; dosing stopped and the company said it would reassess the program.
SourceClinical-stage biotech developing therapies for aging.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Clinical-stage biopharmaceutical company using longitudinal human-aging data and multi-omics to develop therapies for metabolic disease; lead asset BGE-102 is an oral, brain-penetrant NLRP3 inhibitor for cardiovascular risk and retinal disease. Public GitHub not found.
Primary product
BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor
Founded
2015
Headquarters
Emeryville, California, United States
Team size
51-200
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Clinical-stage cardiometabolic therapeutics
Offices
Richmond, California, United States
Business model
clinical-stage drug development
research collaborations and licensing
public-company financing
Funding
Stage
Public
Total raised
$624.2M
Latest round
Follow-on public offering · Feb 2026
Latest amount
$132.3M
Feb 2026
Sep 2024
Feb 2024 · Sofinnova Investments
Dec 2020 · Andreessen Horowitz and Elad Gil
Jan 2019 · Felicis Ventures
Jul 2017 · Andreessen Horowitz Bio Fund
People & investors
Leadership
Co-Founder, CEO
Co-Founder, COO
CMO & EVP, Research
Chief Financial Officer
Chief Business Officer & Therapeutic Area Head, Brain Aging
Chief Development Officer
Chief Strategy Officer
Investors
AARP Foundation
AME Cloud Ventures
Amgen Ventures
Andreessen Horowitz
Caffeinated Capital
Citigroup
Cormorant Asset Management
Elad Gil
Felicis Ventures
Goldman Sachs
Jefferies
Kaiser Foundation Hospitals
Khosla Ventures
Lilly Ventures
Longitude Capital
Morgan Stanley
OrbiMed Advisors
Osage University Partners
PEAR Ventures
Phi-X Capital
Pivotal bioVenture Partners
RA Capital
Redpoint Ventures
RTW Investments
Sands Capital
Sofinnova Investments
SV Health Investors
Work & culture
Mission-driven, science-heavy, and flexible; careers page describes a remote-first culture focused on aging biology and metabolic disease discovery.
Work style
Remote
Compensation
No public salary bands found; public compensation signals are limited to a benefits-and-stipends package rather than disclosed pay ranges.
Benefits
health insurance
dental insurance
vision insurance
FSA
childcare benefits
fertility benefits
life insurance
disability coverage
401(k)
technology stipend
continuing education stipend
Product & market
Pricing
No public pricing; monetization appears to come from therapeutic development, collaboration revenue, licensing, and eventual drug commercialization.
Differentiators
- —human-first discovery platform built on proprietary longitudinal human aging data
- —multi-omics approach to identify molecular mediators of aging
- —oral, brain-penetrant NLRP3 inhibitor with strong hsCRP reductions
- —pipeline spanning cardiovascular, ocular, and metabolic indications
- —focus on aging biology as an upstream disease driver
Technology
Apache Jena
SPARQL
Neo4j
GitHub
Python
Docker
Google Cloud Platform
Vercel
TypeScript
Rippling
NetSuite
OpenAI
Hugging Face
FlowJo
Zoom
Google Meet
Gmail
DocuSign
Harvest
Adobe
Customers
Novartis
Eli Lilly
patients with obesity and cardiometabolic disease
Competitors
ORIC Pharmaceuticals
Bright Peak Therapeutics
Vigil Neuroscience
Ventyx Biosciences
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
9.5K
Signals & risks
Other
Jan 2025BioAge terminated development of azelaprag and shifted focus to next-generation APJ and NLRP3 programs after the STRIDES discontinuation.
SourceOther
Jan 2025A securities class action was filed after the IPO alleging BioAge’s offering materials failed to adequately disclose risks around the azelaprag/STRIDES trial safety profile.
SourceLatest news
BioAge Labs · Jun 2026
First participant dosed in QUELL-CV, a randomized, placebo-controlled Phase 2 proof-of-concept trial of BGE-102 for elevated cardiovascular risk; topline data anticipated H2 2026.
BioAge Labs · May 2026
Reported positive April 2026 Phase 1 data for BGE-102 and outlined plans to start Phase 2 cardiovascular-risk and DME trials in mid-2026.
BioAge Labs · Apr 2026
BGE-102 showed potential best-in-class hsCRP reductions and a favorable tolerability profile in Phase 1.
BioAge Labs · Jan 2026
Priced an upsized public offering for approximately $115.0 million gross proceeds, later increased with full overallotment exercise.
Reuters · Dec 2024
Company discontinued the STRIDES Phase 2 azelaprag trial after liver-enzyme elevations were observed in some participants.
Jobs and careers at BioAge Labs
6 jobs at BioAge Labs
Senior Clinical Trial Manager - Ophthalmology
Remote
R&D
Remote (United States)
Today
Remote
Full-time
Senior Director, Clinical Operations
Remote
R&D
Remote (United States)
Today
Remote
Full-time
Director, DMPK (or Senior Director)
Remote
R&D
Remote (United States)
1mo ago
Remote
Full-time
Director, Clinical Science
Remote
R&D
Remote (United States)
1mo ago
Remote
Full-time
Director, Clinical Supply Chain (or Senior)
Remote
R&D
Remote (United States)
1mo ago
Remote
Full-time
Clinical Trial Manager (or Senior)
Remote
R&D
Remote (United States)
1mo ago
Remote
Full-time